Visser PJ - Search Results

1

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.

Ten Kate M, Barkhof F, Boccardi M, Visser PJ, Jack CR Jr, Lovblad KO, Frisoni GB, Scheltens P; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Ten Kate M, et al. Among authors: visser pj. Neurobiol Aging. 2017 Apr;52:167-182.e1. doi: 10.1016/j.neurobiolaging.2016.05.024. Neurobiol Aging. 2017. PMID: 28317647 Review.

2

Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment.

Visser PJ, Scheltens P, Verhey FR, Schmand B, Launer LJ, Jolles J, Jonker C. Visser PJ, et al. J Neurol. 1999 Jun;246(6):477-85. doi: 10.1007/s004150050387. J Neurol. 1999. PMID: 10431775

3

Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment.

Visser PJ, Verhey FR, Hofman PA, Scheltens P, Jolles J. Visser PJ, et al. J Neurol Neurosurg Psychiatry. 2002 Apr;72(4):491-7. doi: 10.1136/jnnp.72.4.491. J Neurol Neurosurg Psychiatry. 2002. PMID: 11909909 Free PMC article.

4

Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects.

Visser PJ, Verhey FR, Scheltens P, Cruts M, Ponds RW, Van Broeckhoven CL, Jolles J. Visser PJ, et al. J Neurol. 2002 Mar;249(3):312-9. doi: 10.1007/s004150200011. J Neurol. 2002. PMID: 11993532 Clinical Trial.

5

Diagnosis of preclinical Alzheimer's disease in a clinical setting.

Visser PJ, Verhey FR, Ponds RW, Jolles J. Visser PJ, et al. Int Psychogeriatr. 2001 Dec;13(4):411-23. doi: 10.1017/s1041610201007839. Int Psychogeriatr. 2001. PMID: 12003248

6

Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.

Korf ES, Wahlund LO, Visser PJ, Scheltens P. Korf ES, et al. Among authors: visser pj. Neurology. 2004 Jul 13;63(1):94-100. doi: 10.1212/01.wnl.0000133114.92694.93. Neurology. 2004. PMID: 15249617

7

Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease.

Karas GB, Scheltens P, Rombouts SA, Visser PJ, van Schijndel RA, Fox NC, Barkhof F. Karas GB, et al. Among authors: visser pj. Neuroimage. 2004 Oct;23(2):708-16. doi: 10.1016/j.neuroimage.2004.07.006. Neuroimage. 2004. PMID: 15488420 Clinical Trial.

8

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.

Visser PJ, Scheltens P, Pelgrim E, Verhey FR; Dutch ENA-NL-01 Study Group. Visser PJ, et al. Dement Geriatr Cogn Disord. 2005;19(2-3):126-33. doi: 10.1159/000082883. Epub 2004 Dec 23. Dement Geriatr Cogn Disord. 2005. PMID: 15627759

9

Biomarker profiles and their relation to clinical variables in mild cognitive impairment.

Schoonenboom SN, Visser PJ, Mulder C, Lindeboom J, Van Elk EJ, Van Kamp GJ, Scheltens PH. Schoonenboom SN, et al. Among authors: visser pj. Neurocase. 2005 Feb;11(1):8-13. doi: 10.1080/13554790490896785. Neurocase. 2005. PMID: 15804919

10

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

Visser PJ, Scheltens P, Verhey FR. Visser PJ, et al. J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1348-54. doi: 10.1136/jnnp.2004.047720. J Neurol Neurosurg Psychiatry. 2005. PMID: 16170074 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

365 results

Search Page